Novanta Inc. $NOVT Shares Sold by Vanguard Group Inc.

Key Points

• Vanguard Group trimmed its Novanta stake by 0.9% in Q4, selling 38,190 shares but still holds 4,340,698 shares—about 12.13% of the company valued at roughly $516.5 million.
• Insider selling has been notable: CFO Robert Buckley sold 9,957 shares and CEO Matthijs Glastra sold 6,500 shares, with insiders offloading 25,380 shares (~$3.30M) in the past 90 days and now owning 1.20% of the stock.
• Analysts are mixed with an average rating of "Hold" and an average target of $144, while Novanta issued FY2026 EPS guidance of 3.50–3.65 (Q1 guidance 0.75–0.80) after a slight quarterly EPS beat.

Vanguard Group Inc. trimmed its stake in shares of Novanta Inc. (NASDAQ:NOVT - Free Report) by 0.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,340,698 shares of the technology company's stock after selling 38,190 shares during the quarter. Vanguard Group Inc. owned about 12.13% of Novanta worth $516,500,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. Pilgrim Partners Asia Pte Ltd purchased a new position in shares of Novanta during the 3rd quarter worth approximately $36,000. Migdal Insurance & Financial Holdings Ltd. purchased a new position in shares of Novanta during the 3rd quarter worth approximately $40,000. Danske Bank A S purchased a new position in shares of Novanta during the 3rd quarter worth approximately $40,000. Farther Finance Advisors LLC raised its stake in shares of Novanta by 1,291.4% during the 4th quarter. Farther Finance Advisors LLC now owns 487 shares of the technology company's stock worth $58,000 after buying an additional 452 shares in the last quarter. Finally, Assetmark Inc. raised its stake in shares of Novanta by 22.4% during the 4th quarter. Assetmark Inc. now owns 541 shares of the technology company's stock worth $64,000 after buying an additional 99 shares in the last quarter. 98.35% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Novanta

In other news, CFO Robert Buckley sold 9,957 shares of the firm's stock in a transaction on Monday, March 16th. The stock was sold at an average price of $116.77, for a total transaction of $1,162,678.89. Following the sale, the chief financial officer owned 96,616 shares in the company, valued at $11,281,850.32. This trade represents a 9.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Matthijs Glastra sold 6,500 shares of the firm's stock in a transaction on Friday, April 17th. The stock was sold at an average price of $130.05, for a total value of $845,325.00. Following the sale, the chief executive officer owned 56,761 shares in the company, valued at $7,381,768.05. This trade represents a 10.27% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 25,380 shares of company stock worth $3,296,276 in the last 90 days. Insiders own 1.20% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on NOVT shares. Weiss Ratings reissued a "hold (c-)" rating on shares of Novanta in a research note on Friday, April 17th. Zacks Research raised Novanta from a "strong sell" rating to a "hold" rating in a research note on Friday, January 16th. Robert W. Baird raised Novanta from a "neutral" rating to an "outperform" rating and cut their target price for the stock from $150.00 to $144.00 in a research note on Monday, March 30th. Finally, Wall Street Zen downgraded Novanta from a "buy" rating to a "hold" rating in a research note on Saturday, April 18th. One investment analyst has rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of "Hold" and an average target price of $144.00.

Novanta Stock Performance

Novanta stock opened at $126.08 on Tuesday. The company has a debt-to-equity ratio of 0.16, a quick ratio of 2.80 and a current ratio of 3.69. The stock has a fifty day moving average of $126.19 and a two-hundred day moving average of $124.42. The company has a market capitalization of $4.49 billion, a price-to-earnings ratio of 86.36 and a beta of 1.62. Novanta Inc. has a fifty-two week low of $98.27 and a fifty-two week high of $149.95.

Novanta (NASDAQ:NOVT - Get Free Report) last released its quarterly earnings results on Monday, February 23rd. The technology company reported $0.91 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.03. The company had revenue of $258.35 million during the quarter, compared to the consensus estimate of $260.72 million. Novanta had a return on equity of 13.12% and a net margin of 5.49%.During the same quarter last year, the business posted $0.76 earnings per share. Novanta has set its FY 2026 guidance at 3.500-3.650 EPS and its Q1 2026 guidance at 0.750-0.800 EPS. On average, analysts anticipate that Novanta Inc. will post 3.54 EPS for the current fiscal year.

Novanta Profile

Novanta, Inc NASDAQ: NOVT is a global technology company that designs and manufactures precision components, subsystems and software used in advanced photonics and motion control applications. The company serves customers in the medical device and advanced industrial markets, supplying critical technologies for diagnostics and therapeutic systems, semiconductor and electronics manufacturing, and scientific instrumentation. Novanta's product portfolio includes laser control modules, optics, beam delivery systems, high-precision motors, actuators, stages, and fluidics solutions designed to meet stringent accuracy and reliability requirements.

Novanta's Photonics segment delivers laser and energy delivery components that enable minimally invasive surgical procedures and diagnostic imaging.

Want to see what other hedge funds are holding NOVT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novanta Inc. (NASDAQ:NOVT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.